Bedrijfsoverzicht
Intelligent Bio Solutions Inc. is a medical technology enterprise dedicated to the development and delivery of non-invasive testing and screening solutions across the Asia Pacific, United States, United Kingdom, and international markets. The company specifically operates an intelligent fingerprinting drug screening system, which serves as a core platform for its product offerings. Operating within the healthcare sector, the firm functions specifically in the medical devices industry, a classification that implies a focus on hardware and diagnostic equipment rather than pharmaceuticals or services. With a market capitalization of $4.92 million and an annual revenue of $3.58 million, the company maintains a relatively small scale in the global market. The market cap figure indicates that Intelligent Bio Solutions Inc. is a small-cap entity, suggesting a niche position with limited liquidity compared to large-cap peers, while the revenue level reflects a specialized operational footprint supported by a workforce of 53 employees.
Financiële gezondheid
The company reported revenue of $3.58 million over the trailing twelve months, yet recorded a net income loss of $11,294,226, revealing a significant negative gap between top-line growth and bottom-line profitability. This substantial disparity indicates a cost structure where operating expenses and other costs far exceed the gross profit generated from sales, resulting in a net loss that is disproportionate to the revenue base. The firm generated an EBITDA of $-9,836,561, which further highlights the operational challenges in converting revenue into operating cash earnings before interest and taxes. Free cash flow stands at $-14,541,733, indicating that the company is burning cash rather than generating liquidity, which limits its financial flexibility for capital expenditures or debt repayment without external financing. Margin analysis shows a gross margin of 46.2%, suggesting the products have moderate pricing power or cost efficiency at the manufacturing level. However, the operating margin is negative at -290.9%, and the profit margin is 0.0%, confirming that general and administrative costs are consuming the entire gross profit and then some. The company holds $740,371 in cash against a debt load of $1.92 million, resulting in a debt-to-equity ratio of 17.67, which characterizes the balance sheet as highly leveraged rather than conservative. Despite the high debt relative to equity, the current ratio of 2.38 suggests that the company possesses sufficient current assets to cover its short-term liabilities, indicating a degree of short-term liquidity stability. Furthermore, the return on equity is -150.2% and the return on assets is -51.2%, metrics that reveal that management is currently destroying shareholder value and utilizing assets inefficiently to generate positive returns.
Waarderingsbeoordeling
The P/E ratio based on trailing twelve-month earnings is N/A due to the net loss, whereas the forward P/E is 7.03, implying that the market is pricing in a future transition to profitability or earnings recovery. The price-to-book ratio stands at 0.27, indicating that the stock trades at a significant discount to its book value, suggesting the market undervalues the company's assets or anticipates continued struggles. The price-to-sales ratio is 1.37, and the EV/EBITDA is -0.50; these alternative valuation metrics suggest that the market is focusing on revenue multiples rather than earnings multiples due to the lack of current profitability. The stock has a 52-week high of $24.90 and a 52-week low of $2.46, meaning the current trading price sits significantly below the recent peak but remains well above the yearly floor. The beta value of 4.59 indicates that the stock exhibits extreme price volatility relative to the broader market, moving more than four times as much as the market index during periods of fluctuation.
Growth & Income
Revenue growth year-over-year is recorded at 47.6%, demonstrating strong top-line expansion, while earnings growth is N/A because the company is currently unprofitable. Since earnings are negative, they cannot grow faster or slower than revenue in a traditional sense, but the trajectory suggests that top-line momentum exists despite the lack of earnings growth. As a non-dividend payer, the company does not distribute cash to shareholders, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, implying that any generated cash or existing reserves are likely reinvested into operations or used to service debt rather than paid out. The overall growth and income profile presents a high-risk scenario characterized by rapid revenue expansion coupled with deep losses and no current income distribution to investors.